PGT Explained: Which Embryo Genetic Test Is Right for Your Family?
You are being handed choices before you understand the menu. Here is what each test actually does, what it costs, and when it meaningfully changes the decision.
The science is real. The pricing is fragmented. Here is how to read both.
Published 18 May 2026 · IVF Daddies
Verified: IVF Daddies · 2026
Bottom Line Up Front
We are not doctors. We have never claimed to be. We are people who spent years learning to read a system that was not built to be readable. When something this complex moves, we translate it. Not for the insiders. For you. For the intended parent sitting with a clinic consent form covered in acronyms, trying to figure out what is medically necessary, what is genuinely optional, and what the difference actually costs.
| What is new in PGT | What has not changed |
|---|---|
| PGT is now a multi-lane spectrum covering chromosomes, single genes, structural rearrangements, and polygenic risk. | The embryo biology. PGT does not fix embryos. It reads them. |
| ASRM drew a hard line in late 2025 against PGT-P as standard clinical care. | The sticker shock. Clinics still frequently split biopsy and lab fees into separate quotes. |
| Northern Europe developed a single unified test replacing the slow per-family probe process for PGT-M. | The transfer trauma. The desire to minimize miscarriage and shorten time to a live birth. |
| The legal geography of reproductive law now defines which breakthroughs are accessible depending on where you receive care. | The fundamental question. What problem are we trying to solve for our family. |
They added the acronyms. Did anything else change?
PGT used to be a binary conversation. You either screened chromosomes to reduce miscarriage risk, or you tested for a specific inherited disease. Now medicine treats the embryo like a complete genomic sequence.
Same embryo. Different layers of information depending on which clinic you walk into, how much you are willing to spend, and what kind of certainty your family needs to move forward.
The technology expanded. The medical system has not fully standardized how it talks about it yet. And the pricing structures have not caught up either.
The useful question is not which test to buy. The useful question is what problem you are trying to solve.
Is your doctor current or stuck?
You do not need to be a molecular geneticist to find out. You just need to ask one question.
"What specific problem is this specific PGT type trying to solve for my family architecture?"
Three things happen.
They break down your actual data points, your age, embryo yield, miscarriage history, donor status, and explain why a specific test shifts your odds or why it is purely optional. Good doctor. Keep going.
They say "everyone does it" and hand you a generic consent form without looking at your file. Watch carefully. Ask what the clinical justification is for your specific prognosis.
They pitch PGT-P as standard clinical care to screen your future child for adult heart disease or diabetes. Ask them: "Are you practicing according to the late 2025 ASRM guidance on polygenic embryo screening?" Their answer tells you where you stand.
If your doctor is behind, you have choices. You can slow the room down and draw your own boundaries around what you are willing to spend and test for.
What PGT actually means
Genetic testing performed on an embryo before it is transferred. PGT is an umbrella term, not a single test. Each type answers a different biological question about a different layer of the embryo's genetics.
How PGT happens
The four tests: one card for each
Same question throughout: what problem does this solve?
California costs: what a full cycle actually looks like
Clinics frequently quote the biopsy fee and the reference lab analysis separately, or omit one entirely. Always ask for a line-item total covering both.
Who benefits: medical strategy and peace of mind are not the same thing
This is where medicine rarely gives a clear answer and where the internet makes it binary. IVF Daddies holds both.
- PGT-M when a known inherited condition is being tracked
- PGT-SR when recurrent unexplained loss points to structural rearrangement
- PGT-A when maternal age, miscarriage history, or transfer complexity creates clear clinical benefit
- Test type matched to a specific, identifiable medical problem
- PGT-A for families who have the resources and want to reduce uncertainty
- Knowing every transferred embryo was screened changes the emotional experience of the wait
- For surrogacy journeys with high operational stakes, added certainty has compounding value
- Peace of mind is a real variable. It belongs in this decision.
Where the breakthroughs happen, and why
Reproductive law is not a bureaucratic detail. It is the reason certain advances exist in certain places.
The decoder close
The question to carry into the clinic room
"What problem are we trying to solve for our family, and does this test meaningfully help solve it?"
Medicine became more sophisticated. That does not always mean it became easier to navigate. We are not here to practice medicine. We are here to make the room more readable.
Frequently Asked Questions
Sources: ASRM Committee Opinion on PGT-A (2024), ASRM Indications for PGT-M (2023), ASRM Ethics Committee Report on Polygenic Embryo Screening (2025), IVI RMA clinical research, Karolinska Institutet and Maastricht University published research.
IVF Daddies Newsletter
Structural briefings on policy, clinical, and regulatory developments.
Weekly updates on family-building governance.